Diligence memo · auto-generated · as of July 2, 2026
Imel Biotherapeutics, Inc.
Imel Biotherapeutics, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Imel Biotherapeutics, Inc. operates in Other Health Care, based in WALTHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Imel Biotherapeutics, Inc. has raised $15M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $15M on 2021-10-29.
Most recent recorded round closed around 2021-10-29.
Valuation (modeled)modeled
Provath models Imel Biotherapeutics, Inc. at approximately $222M (range $35M–$664M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.59× the median modeled value of Series B Other Health Care companies in 2019–2021 (78 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.7 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 81% of Other Health Care peers (5377 compared).
Modeled value ranks above 89% of those peers.
Closest niche peers: KSMS Holdings, LLC, Infab HoldCo, Inc., Aquity Holdings, Inc., MHH Management Holdco, LLC, Earli Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.